نتایج جستجو برای: allogeneic bmt

تعداد نتایج: 28117  

Journal: :Blood 2003
Tamotsu Ichiba Takanori Teshima Rork Kuick David E Misek Chen Liu Yuichiro Takada Yoshinobu Maeda Pavan Reddy Debra L Williams Samir M Hanash James L M Ferrara

The liver, skin, and gastrointestinal tract are major target organs of acute graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation (BMT). In order to gain a better understanding of acute GVHD in the liver, we compared the gene expression profiles of livers after experimental allogeneic and syngeneic BMT using oligonucleotide microarray. At 35 days af...

Journal: :Blood 1997
G R Hill J M Crawford K R Cooke Y S Brinson L Pan J L Ferrara

The influence of bone marrow transplantation (BMT) conditioning regimens on the incidence and severity of graft-versus-host disease (GVHD) has been suggested in clinical BMT. Using murine BMT models, we show here an increase in GVHD severity in several donor-recipient strain combinations after intensification of the conditioning regimen by increasing the total body irradiation (TBI) dose from 9...

Journal: :Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002
Bryon D Johnson Patricia A Taylor Marja C Stankowski Sohel Talib John E Hearst Bruce R Blazar

Donor T-cells can provide a graft-versus-leukemia effect and help to promote donor engraftment after allogeneic BMT; however, these benefits can be outweighed by the ability of the cells to induce life-threatening GVHD. Photochemical treatment (PCT) of T-cells with S-59 psoralen and long-wavelength UV-A light can inhibit their proliferative capacity and significantly decrease their ability to i...

Journal: :Blood 1996
S Slavin E Naparstek A Nagler A Ackerstein S Samuel J Kapelushnik C Brautbar R Or

Allogeneic bone marrow transplantation (BMT) is the only effective treatment for hematologic malignancies resistant to conventional chemotherapy. Until recently, no cure existed for patients who relapsed post-BMT. We present our long-term observations on remission induction, after relapse post-BMT, by allogeneic cell therapy (allo-CT) and the feasibility of remission induction in allo-CT-resist...

Journal: :Clinical and diagnostic laboratory immunology 2000
N M Blijlevens J P Donnelly J F Meis M H De Keizer B E De Pauw

Procalcitonin (PCT) is an early marker of bacterial infection but little is known about its value in neutropenic allogeneic bone marrow transplant (BMT) recipients. We collected plasma from 12 recipients of T-cell-depleted HLA-matched related BMT recipients who had been treated preemptively with meropenem from the day after BMT for at least 15 days. PCT and C-reactive protein (CRP) concentratio...

Journal: :American journal of clinical pathology 2014
Giovanni Negri Martina Herz Sara Deola Andrea Piccin Marco Casini Bianca Babich Martina Tauber Sergio Messini Maria Raffaella Marucci Fabio Vittadello

OBJECTIVES Allogeneic bone marrow transplantation (BMT) is a procedure mostly used for high-risk hematologic malignances. In women, follow-up protocols after BMT include gynecologic checkups with Papanicolaou (Pap) smears. METHODS We evaluated 117 Pap smears in 54 women who underwent allogeneic BMT and correlated the smear morphology with the BMT-related medical treatment. RESULTS Abnormal ...

Journal: :Blood 1992
C B Miller R J Jones M L Zahurak S Piantadosi W H Burns G W Santos J L Spivak

Delayed erythroid recovery is common after bone marrow transplantation (BMT), with some patients continuing to require red blood cell (RBC) transfusion support for as long as 1 year. While the etiology is multifactorial, inadequate stimulation of erythroid progenitors by the erythroid growth factor, erythropoietin, may play a role. In this study, the erythropoietin response to anemia of 70 cons...

Journal: :Oncology reports 2006
Yuming Zhang Yasushi Adachi Yasuhiro Suzuki Keizo Minamino Masayoshi Iwasaki Keiji Nakano Yasushi Koike Hiromi Mukaide Akio Shigematsu Naoko Kiriyama Chunfu Li Susumu Ikehara

G-CSF and M-CSF are used clinically to augment hematopoiesis after bone marrow transplantation (BMT) and chemotherapy. In this paper, we examined the synergistic effect of G-CSF and M-CSF on hematopoietic recovery in allogeneic BMT as a model of human BMT. We performed BMT from eGFP-transgenic mice (C57BL/6 background; H-2b) into lethally-irradiated C3H (H-2k). From the day after BMT, G-CSF and...

Journal: :Blood 1994
G Pichert E P Alyea R J Soiffer D C Roy J Ritz

Previous studies have shown that tumor-specific bcr-abl mRNA can often be detected by polymerase chain reaction. (PCR) for months to years after allogeneic bone marrow transplantation (BMT) for chronic myelocytic leukemia (CML). Nevertheless, the presence of bcr-abl mRNA by itself does not invariably predict for clinical relapse post-BMT. This has led to the hypothesis that bcr-abl mRNA might b...

Journal: :Blood 1999
E K Waller A M Ship S Mittelstaedt T W Murray R Carter I Kakhniashvili S Lonial J T Holden M W Boyer

Graft rejection in allogeneic bone marrow transplantation (BMT) can occur when donor and recipient are mismatched at one or more major histocompatibility complex (MHC) loci. Donor T cells can prevent graft rejection, but may cause fatal graft-versus-host disease (GVHD). We tested whether irradiation of allogeneic donor lymphocytes would preserve their graft-facilitating activity while inhibitin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید